| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||||||
Net loss | ||||||||||
-83,993 | -175,149 | -114,397 | -167,211 | -157,803 | -100,048 | -46,514 | -52,421 | -28,675 | -11,556 | -9,128 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||
Depreciation and other amortization | ||||||||||
34,212 | 20,544 | 14,572 | 11,309 | 7,600 | 3,710 | 1,418 | 985 | 411 | 230 | 80 |
Loss on disposal of property, plant and equipment | ||||||||||
-1,394 | -353 | -954 | -151 | -40 | -49 | -100 | - | - | - | - |
Realized gain on sale of marketable securities | ||||||||||
3,355 | 385 | 23 | - | - | - | - | - | - | - | - |
Unrealized loss on revaluation of marketable equity securities | ||||||||||
-207 | 0 | 0 | - | - | - | - | - | - | - | - |
Loss on preferred stock investment | ||||||||||
0 | -765 | 0 | - | - | - | - | - | - | - | - |
Deferred tax benefit | ||||||||||
-185,109 | 0 | -115 | - | - | - | - | - | - | - | - |
Stock-based compensation | ||||||||||
108,500 | 60,300 | 35,500 | 23,732 | 18,050 | 11,520 | 7,744 | 5,493 | 3,964 | 2,121 | 2,631 |
Loss on settlement of convertible notes | ||||||||||
10,558 | 0 | 0 | - | - | - | - | - | - | - | - |
Amortization of convertible note debt discount and issuance costs | ||||||||||
42,256 | 28,564 | 0 | - | - | - | - | - | - | - | - |
Amortization of liabilities | ||||||||||
4,467 | 2,394 | 1,620 | 1,013 | 573 | - | - | - | - | - | - |
Amortization of debt issuance costs | ||||||||||
- | - | - | - | 44 | - | - | - | - | - | - |
Amortization of deferred license fees | ||||||||||
- | - | - | - | - | 294 | 4,144 | -4,144 | -4,143 | -5,318 | -4,733 |
Amortization of deferred financing costs | ||||||||||
- | - | - | 52 | - | - | - | - | - | - | - |
Amortization of premium on short-term investments | ||||||||||
-3,102 | -3,516 | 88 | 463 | 1,323 | 842 | 636 | 532 | 360 | 37 | - |
Forgiveness of long-term debt | ||||||||||
- | - | - | - | 1,000 | - | - | - | - | - | - |
Warrant licensing expense | ||||||||||
- | - | - | - | - | - | - | 152 | 107 | 107 | 1,779 |
Restricted stock licensing expense | ||||||||||
- | - | - | - | - | - | - | 1,000 | - | - | - |
Amortization of acquired intangible assets | ||||||||||
16,035 | 2,540 | 983 | 200 | 150 | - | - | - | - | - | 95 |
Non-cash lease expense | ||||||||||
5,427 | 0 | 0 | - | - | - | - | - | - | - | - |
Proceeds from refundable tax credits | ||||||||||
- | - | - | 800 | - | - | - | - | - | - | - |
Changes in assets and liabilities: | ||||||||||
Accrued interest | ||||||||||
- | - | - | - | -106 | 22 | 21 | 21 | 21 | 20 | 1 |
Accounts receivable, net | ||||||||||
27,938 | 17,292 | 17,529 | 3,593 | 3,557 | 1,376 | - | - | - | - | - |
Inventory | ||||||||||
19,041 | 12,729 | 19,194 | 156 | 2,660 | 4,017 | - | - | - | - | - |
Operating lease liabilities | ||||||||||
-4,114 | 0 | 0 | - | - | - | - | - | - | - | - |
Prepaid expenses and other current assets | ||||||||||
- | - | - | -761 | 3,057 | 1,329 | 1,606 | -441 | 788 | -238 | 294 |
Accounts payable and accrued liabilities | ||||||||||
3,469 | 33,076 | 30,537 | -2,598 | 661 | 1,886 | -2,891 | 2,887 | -263 | 873 | -528 |
Other assets and liabilities | ||||||||||
5,932 | 3,966 | 1,492 | - | - | - | - | - | - | - | - |
Accrued liabilities | ||||||||||
- | - | - | 7,349 | 7,424 | 8,064 | 2,299 | 532 | 1,542 | 795 | -81 |
Lease incentive obligation | ||||||||||
- | - | - | -312 | -553 | -487 | 2,655 | - | - | - | - |
Net cash used in operating activities | ||||||||||
-115,010 | -69,325 | -71,724 | -130,066 | -134,017 | -81,458 | -40,282 | -44,522 | -27,464 | -13,441 | -12,640 |
Third party royalty obligation | ||||||||||
- | - | - | - | - | - | - | - | - | -988 | -2,462 |
Cash flows from investing activities: | ||||||||||
Purchases of marketable securities | ||||||||||
634,117 | 1,192,506 | 357,051 | 189,989 | 205,054 | 209,471 | 98,510 | 96,047 | 87,017 | 24,498 | 18,879 |
Maturities and sales of marketable securities | ||||||||||
1,660,559 | 579,171 | 271,466 | 193,321 | 162,283 | 104,172 | 72,289 | 58,411 | 45,725 | 10,204 | 16,474 |
Purchases of property, plant and equipment | ||||||||||
171,802 | 150,093 | 48,480 | 14,851 | 20,084 | 11,991 | 8,748 | 681 | 2,115 | 626 | 462 |
Business combination, net of cash acquired | ||||||||||
973,861 | 17,908 | 2,980 | - | - | - | - | - | - | - | - |
Purchases of intangible assets | ||||||||||
0 | 0 | 20,690 | - | 1,900 | - | - | - | - | - | - |
Other investing activities | ||||||||||
1,852 | 578 | 3,070 | - | - | - | - | - | - | - | - |
Net cash used in investing activities | ||||||||||
-121,073 | -781,914 | -160,805 | -11,519 | -64,755 | -117,290 | -34,969 | -38,317 | -43,407 | -14,920 | -2,867 |
Cash flows from financing activities: | ||||||||||
Proceeds from issuance of convertible notes, net | ||||||||||
729,477 | 896,430 | 0 | - | - | - | - | - | - | - | - |
Proceeds from financing obligation, net payments on mortgage payable | ||||||||||
0 | 2,084 | -174 | - | - | - | - | - | - | - | - |
Proceeds from exercise of common stock options | ||||||||||
8,787 | 6,636 | 5,103 | 3,411 | 1,248 | 2,640 | 1,341 | 2,388 | 685 | 466 | 732 |
Proceeds from Genzyme Collaboration, License and Purchase Agreement | ||||||||||
- | - | - | - | - | - | - | - | - | 1,896 | 16,650 |
Proceeds from sale of common stock to Genzyme | ||||||||||
- | - | - | - | - | - | - | - | - | - | 6,000 |
Proceeds from sale of common stock, net of issuance costs | ||||||||||
0 | 0 | 253,388 | 144,242 | 174,140 | 238,580 | 73,296 | 57,755 | 27,215 | 82,327 | 8,062 |
Proceeds from New Market Tax Credit financing agreements | ||||||||||
- | - | - | - | - | 2,399 | - | - | - | - | - |
Proceeds in connection with the Company's employee stock purchase plan | ||||||||||
8,396 | 4,895 | 2,841 | 2,099 | 1,719 | 760 | 453 | 367 | - | - | - |
Payments on settlement of convertible notes | ||||||||||
493,356 | 0 | 0 | - | - | - | - | - | - | - | - |
Proceeds from construction loan | ||||||||||
319 | 24,236 | -202 | - | - | - | - | - | - | - | - |
Payments on mortgage payable | ||||||||||
- | - | - | 166 | 44 | - | - | - | - | - | - |
Other financing activities | ||||||||||
442 | 139 | 0 | - | - | - | - | - | - | - | - |
Payments on capital lease | ||||||||||
- | - | - | - | 360 | 351 | 333 | 107 | - | - | - |
Proceeds from Mortgage Payable | ||||||||||
- | - | - | - | 5,062 | - | - | - | - | - | - |
Net cash provided by financing activities | ||||||||||
253,181 | 934,142 | 260,956 | 149,586 | 181,765 | 244,028 | 74,757 | 60,403 | 27,900 | 85,189 | 32,494 |
Effects of exchange rate changes on cash and cash equivalents | ||||||||||
0 | 36 | 143 | -215 | 11 | - | - | - | - | - | - |
Decrease in restricted cash | ||||||||||
- | - | - | - | - | - | - | - | - | 500 | 100 |
Payment for repurchase of stock options | ||||||||||
- | - | - | - | - | - | - | - | - | - | 50 |
Proceeds from long term debt | ||||||||||
- | - | - | - | - | - | - | - | - | - | 1,000 |
Net increase in cash and cash equivalents | ||||||||||
17,098 | 82,939 | 28,570 | 7,786 | -16,996 | 45,280 | -494 | -22,436 | -42,971 | 56,828 | 16,987 |
Supplemental disclosure of non-cash investing and financing activities: | ||||||||||
Property, plant and equipment acquired but not paid | ||||||||||
10,265 | 33,452 | 8,818 | 655 | 1,705 | 546 | 534 | - | - | - | - |
Property acquired under build-to-suit lease | ||||||||||
0 | 2,092 | 0 | - | - | - | - | - | - | - | - |
Unrealized gain (loss) on available-for-sale investments, before tax | ||||||||||
1,322 | -708 | -475 | 230 | -329 | -240 | 47 | 92 | -15 | -2 | 1 |
Issuance of 136,559 and 86,532 shares of common stock to fund the Company’s 401(k) matching contribution for 2019 and 2018, respectively | ||||||||||
7,409 | 4,303 | 3,008 | 2,151 | 836 | 456 | 354 | 274 | 169 | 65 | 32 |
Issuance of 2,158,991 shares of common stock upon settlement of convertible notes | ||||||||||
182,477 | 0 | 0 | - | - | - | - | - | - | - | - |
Retirement of equity component of convertible notes settled | ||||||||||
-300,768 | 0 | 0 | - | - | - | - | - | - | - | - |
Issuance of common stock for business combinations | ||||||||||
1,407,080 | 0 | 0 | - | - | - | - | - | - | - | - |
Business acquisition contingent consideration liability | ||||||||||
0 | 3,060 | 0 | - | - | - | - | - | - | - | - |
Supplemental Cash Flow Information [Abstract] | ||||||||||
Interest paid | ||||||||||
9,301 | 4,638 | 201 | 209 | 95 | 29 | 48 | - | - | - | - |
Retirement of 85,550 treasury shares of common stock | ||||||||||
- | - | - | - | - | - | - | - | - | - | 97 |
Conversion of accrued expenses into 59,932, 63,611 and 51,857 shares of common stock in connection with the Company's ESPP for 2013, 2012 and 2011, respectively | ||||||||||
- | - | - | - | - | - | - | - | 291 | 128 | - |
Laboratory equipment acquired with a capital lease | ||||||||||
- | - | - | - | - | - | - | 1,151 | - | - | - |